Mutual of America Capital Management LLC Has $3.08 Million Stake in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Mutual of America Capital Management LLC trimmed its position in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 17.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 99,975 shares of the specialty pharmaceutical company’s stock after selling 21,389 shares during the period. Mutual of America Capital Management LLC owned 0.31% of Collegium Pharmaceutical worth $3,077,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in the company. BlackRock Inc. increased its holdings in Collegium Pharmaceutical by 4.6% during the second quarter. BlackRock Inc. now owns 6,078,319 shares of the specialty pharmaceutical company’s stock worth $130,623,000 after buying an additional 266,330 shares during the last quarter. Vanguard Group Inc. increased its holdings in Collegium Pharmaceutical by 0.8% during the first quarter. Vanguard Group Inc. now owns 2,306,529 shares of the specialty pharmaceutical company’s stock worth $46,962,000 after buying an additional 19,112 shares during the last quarter. Pacer Advisors Inc. increased its holdings in Collegium Pharmaceutical by 68.4% during the fourth quarter. Pacer Advisors Inc. now owns 2,174,718 shares of the specialty pharmaceutical company’s stock worth $66,938,000 after buying an additional 883,380 shares during the last quarter. State Street Corp increased its holdings in Collegium Pharmaceutical by 6.3% during the second quarter. State Street Corp now owns 1,390,693 shares of the specialty pharmaceutical company’s stock worth $24,643,000 after buying an additional 82,526 shares during the last quarter. Finally, Renaissance Technologies LLC boosted its position in Collegium Pharmaceutical by 1.1% during the first quarter. Renaissance Technologies LLC now owns 1,270,118 shares of the specialty pharmaceutical company’s stock worth $25,860,000 after purchasing an additional 13,800 shares during the period.

Wall Street Analysts Forecast Growth

COLL has been the subject of a number of research analyst reports. Needham & Company LLC reaffirmed a “buy” rating and set a $40.00 price objective on shares of Collegium Pharmaceutical in a research report on Thursday, April 11th. Truist Financial lifted their price objective on shares of Collegium Pharmaceutical from $37.00 to $40.00 and gave the stock a “buy” rating in a research report on Monday, February 26th. Piper Sandler reaffirmed an “overweight” rating and set a $39.00 price objective (up from $37.00) on shares of Collegium Pharmaceutical in a research report on Friday, February 23rd. StockNews.com cut shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research report on Friday, March 29th. Finally, Jefferies Financial Group reaffirmed a “hold” rating and set a $37.00 price objective (up from $30.00) on shares of Collegium Pharmaceutical in a research report on Thursday, January 4th. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat.com, Collegium Pharmaceutical currently has an average rating of “Moderate Buy” and a consensus price target of $39.00.

Collegium Pharmaceutical Trading Down 1.9 %

Shares of Collegium Pharmaceutical stock opened at $34.77 on Friday. The firm has a 50-day moving average of $36.82 and a 200-day moving average of $30.72. The stock has a market cap of $1.14 billion, a PE ratio of 29.47 and a beta of 1.03. Collegium Pharmaceutical, Inc. has a 52-week low of $20.83 and a 52-week high of $40.95. The company has a debt-to-equity ratio of 2.48, a quick ratio of 1.10 and a current ratio of 1.17.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its earnings results on Thursday, February 22nd. The specialty pharmaceutical company reported $1.45 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.20 by $0.25. The company had revenue of $149.75 million during the quarter, compared to analysts’ expectations of $147.66 million. Collegium Pharmaceutical had a net margin of 8.50% and a return on equity of 107.39%. As a group, sell-side analysts forecast that Collegium Pharmaceutical, Inc. will post 5.63 EPS for the current year.

Collegium Pharmaceutical Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.